Pulmonx Corporation
LUNGPulmonx Corporation is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
Earnings
Next report
Nov 11, 2026 (in 2 months)Valuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
By net margin
Profile
Pulmonx Corporation is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company provides a comprehensive interventional platform designed to improve lung function and quality of life for patients who remain symptomatic despite medical management and are ineligible for or wish to avoid major surgery. Their solution integrates diagnostic assessment tools with implantable valves to achieve lung volume reduction without surgical intervention.
Pulmonx is a leader in the interventional emphysema space, holding the first FDA pre-market approval for an endobronchial valve and maintaining a significant clinical evidence base.
FAQ
- What is Pulmonx Corporation's market cap?
- Pulmonx Corporation (LUNG) has a market capitalization of $82.0M and trades on NASDAQ.
- What is Pulmonx Corporation's revenue and profitability?
- Pulmonx Corporation generated $88.5M in trailing twelve-month revenue with a net loss of $53.2M, representing a net margin of -60.1%. Gross margin stands at 75.5%, with free cash flow of -$29.4M. The latest reported period is Q1 2026.
- Who are Pulmonx Corporation's competitors?
- Pulmonx Corporation's key competitors include Intuitive Surgical, Theravance Biopharma, Inc., United Therapeutics Corp, and others. These companies compete in similar markets and product categories.
- Where is Pulmonx Corporation headquartered?
- Pulmonx Corporation is headquartered in United States of America and employs approximately 279 people. It has been publicly traded since 2020.
